Skip to main content
Premium Trial:

Request an Annual Quote

MGI Tech, Agilent to Integrate Sequencing Platforms, Lab Information Management Solution

NEW YORK – Agilent Technologies and MGI Tech plan to integrate Agilent's laboratory information management system and MGI's sequencing platforms, the companies said yesterday.

Under a collaboration agreement signed last month at the 14th International Conference on Genomics in China, the firms plan to put together Agilent's SLIMS laboratory information system and MGI's DNBSeq series of sequencing platforms and other life science instruments to achieve a seamless connection between hardware and software.

The Agilent SLIMS combines the functions of a lab information management system and an electronic lab record, including electronic lab notebooks, sample management, workflow management, order management, and data display boards.

DNBSeq is the core technology that powers MGI's various sequencing instruments, including DNA single-chain circularization and DNA nanoball preparation, patterned array slides, DNB loading, combinatorial probe anchor synthesis, paired-end sequencing, and base calling algorithms.

Both companies have tested the integration of their systems in MGI's laboratory in Australia through a collaboration that commenced in 2017.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.